Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 5969 · LABEL Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 353 Exemptions and consideration for certain drugs, devices, and biological products

+15 −0Shown
More for 21 U.S.C. § 353
Read § 353Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)) is amended by adding at the end the following:(6) (A) Notwithstanding any other provision of this Act, in the case of an abortion-inducing drug, the drug shall be deemed to be misbranded unless the drug bears a label that identifies— (i) the name and address of the dispenser; and (ii) the name of the prescriber. (B) No …

§ 353(b)–(c)

Start of § 353 to (b)(4)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(b)(4)(B)(B) (B)
A drug to which paragraph (1) does not apply shall be deemed to be misbranded if at any time prior to dispensing the label of the drug bears the symbol described in subparagraph (A).A drug to which paragraph (1) does not apply shall be deemed to be misbranded if at any time prior to dispensing the label of the drug bears the symbol described in subparagraph (A).
(b)(5)(5) (5)
Nothing in this subsection shall be construed to relieve any person from any requirement prescribed by or under authority of law with respect to drugs now included or which may hereafter be included within the classifications stated in sections 4721, 6001, and 6151 of title 26, or to marihuana as defined in section 4761 of title 26.Nothing in this subsection shall be construed to relieve any person from any requirement prescribed by or under authority of law with respect to drugs now included or which may hereafter be included within the classifications stated in sections 4721, 6001, and 6151 of title 26, or to marihuana as defined in section 4761 of title 26.
(b)(6)(6) [inserted: ]
(b)(6)(A)(A) [inserted: ]
[inserted: Notwithstanding any other provision of this Act, in the case of an abortion-inducing drug, the drug shall be deemed to be misbranded unless the drug bears a label that identifies—]
(b)(6)(A)(i)(i) [inserted: ]
[inserted: the name and address of the dispenser; and]
(b)(6)(A)(ii)(ii) [inserted: ]
[inserted: the name of the prescriber.]
(b)(6)(B)(B) [inserted: ]
[inserted: No State or political subdivision of a State may establish, continue in effect, or enforce a labeling requirement for an abortion-inducing drug that is not at least as stringent as the labeling requirement in subparagraph (A).]
(b)(6)(C)(C) [inserted: ]
[inserted: In this paragraph, the term “abortion-inducing drug”—]
(b)(6)(C)(i)(i) [inserted: ]
[inserted: means a drug that is intended, alone or in combination with 1 or more other drugs, for use or that is in fact used (irrespective of how the drug is labeled) to kill the unborn child of a woman known to be pregnant or to terminate the pregnancy of a woman known to be pregnant; but]
(b)(6)(C)(ii)(ii) [inserted: ]
[inserted: does not include a drug that is intended, alone or in combination with 1 or more other drugs, for use to remove a dead unborn child of a woman known to be pregnant or to treat an ectopic pregnancy.]
(c)(c) Sales restrictions(c) Sales restrictions
(c)(1)(1) (1)
No person may sell, purchase, or trade or offer to sell, purchase, or trade any drug sample. For purposes of this paragraph and subsection (d), the term “drug sample” means a unit of a drug, subject to subsection (b), which is not intended to be sold and is intended to promote the sale of the drug. Nothing in this paragraph shall subject an officer or executive of a drug manufacturer or distributor to criminal liability solely because of a sale, purchase, trade, or offer to sell, purchase, or trade in violation of this paragraph by other employees of the manufacturer or distributor.No person may sell, purchase, or trade or offer to sell, purchase, or trade any drug sample. For purposes of this paragraph and subsection (d), the term “drug sample” means a unit of a drug, subject to subsection (b), which is not intended to be sold and is intended to promote the sale of the drug. Nothing in this paragraph shall subject an officer or executive of a drug manufacturer or distributor to criminal liability solely because of a sale, purchase, trade, or offer to sell, purchase, or trade in violation of this paragraph by other employees of the manufacturer or distributor.

Rest of § 353 unchanged

Step through the changes